Repurposing of the antimalarial agent tafenoquine to combat MRSA

  • mSystems. 2023 Dec 4:e0102623. doi: 10.1128/msystems.01026-23.
Pengfei She  #  1 ,  Yifan Yang  #  1 ,  Linhui Li  1 ,  Yimin Li  1 ,  Shasha Liu  1 ,  Zehao Li  1 ,  Linying Zhou  2 ,  Yong Wu  2
Affiliations
  • 1. Department of Laboratory Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
  • 2. Department of Laboratory Medicine, The Affiliated Changsha Hospital of Xiangya School of Medicine (The First Hospital of Changsha), Central South University, Changsha, China.
  • # Contributed equally.
PMID: 38047647 DOI: 10.1128/msystems.01026-23
Abstract

This study represents the first investigation into the antimicrobial effect of TAF against S. aureus and its potential mechanisms. Our data highlighted the effects of TAF against MRSA planktonic cells, biofilms, and persister cells, which is conducive to broadening the application of TAF. Through mechanistic studies, we revealed that TAF targets Bacterial cell membranes. In addition, the in vivo experiments in mice demonstrated the safety and antimicrobial efficacy of TAF, suggesting that TAF could be a potential Antibacterial drug candidate for the treatment of infections caused by multiple drug-resistant S. aureus.

Keywords
antimicrobial agents; drug repurposing; methicillin-resistant Staphylococcus aureus; tafenoquine.
Products
Inhibitors & Agonists
Other Products